Published in CPT Pharmacometrics Syst Pharmacol on December 11, 2015
Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis. Oncotarget (2017) 0.75
Looking beyond the cancer cell for effective drug combinations. Genome Med (2016) 0.75
Modeling Longitudinal Preclinical Tumor Size Data to Identify Transient Dynamics in Tumor Response to Antiangiogenic Drugs. CPT Pharmacometrics Syst Pharmacol (2016) 0.75
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol (2004) 10.55
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov (2004) 9.96
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
Role of angiogenesis in tumor growth and metastasis. Semin Oncol (2002) 9.77
The search for synergy: a critical review from a response surface perspective. Pharmacol Rev (1995) 8.24
Sunitinib: from rational design to clinical efficacy. J Clin Oncol (2007) 7.26
Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol (2006) 7.19
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol (2010) 5.21
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol (2010) 4.81
Continuous and discrete mathematical models of tumor-induced angiogenesis. Bull Math Biol (1998) 3.65
Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res (2007) 2.97
Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res (1999) 2.58
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol (2007) 2.51
Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res (2004) 2.47
Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model. J Pharmacokinet Pharmacodyn (2006) 1.45
A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis. CPT Pharmacometrics Syst Pharmacol (2014) 1.30
A model of vascular tumour growth in mice combining longitudinal tumour size data with histological biomarkers. Eur J Cancer (2010) 0.96
Early antivascular effects of bevacizumab anti-VEGF monoclonal antibody on colorectal carcinomas assessed with functional CT imaging. Am J Clin Oncol (2007) 0.96
Sorafenib: targeting multiple tyrosine kinases in cancer. Recent Results Cancer Res (2014) 0.93
Modeling of human tumor xenografts and dose rationale in oncology. Drug Discov Today Technol (2013) 0.91
Theoretical investigation of the efficacy of antiangiogenic drugs combined to chemotherapy in xenografted mice. J Theor Biol (2012) 0.87
Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts. Cancer Chemother Pharmacol (2013) 0.86
A predictive pharmacokinetic-pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination. Cancer Chemother Pharmacol (2013) 0.82
The dynamics of tumour-vasculature interaction suggests low-dose, time-dense anti-angiogenic schedulings. Cell Prolif (2009) 0.79
Prediction of Response to Temozolomide in Low-Grade Glioma Patients Based on Tumor Size Dynamics and Genetic Characteristics. CPT Pharmacometrics Syst Pharmacol (2015) 0.75